Financial releases

Crossject signs a Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Defense (DOD)

First-half 2019 results and business update

business up date : Focus on progress during last summer

Commercial agreement with DESITIN Pharma for ZENEO® Midazolam in Germany

End of the conversion of convertible bonds issued in 2018

Crossject - Slideshow Annual results 2018

Financial results 2018

Crossject : €1.1 million in funding granted jointly by Bpifrance and the Bourgogne Franche-Comté region

CROSSJECT- Gain of pharmaceutical establishment status

SUCCESS OF THE €4 MILLION CAPITAL INCREASE